Elicera Therapeutics AB (ELIC) — Cash Flow Reinvestment Rate
Latest as of December 2023:
0.00x
Elicera Therapeutics AB (ELIC) has a Cash Flow Reinvestment Rate of 0.00x as of December 2023, reinvesting Skr2.00K (capex Skr1.00K plus investments Skr-1.00K) from operating cash flow of Skr3.50 Million. Check earnings quality score of Elicera Therapeutics AB to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
0.00x
(Capex + Investments) / Operating CF
Total Reinvested
Skr2.00K
Capex + Investments
Operating Cash Flow
Skr3.50 Million
SEK
Capital Expenditures
Skr1.00K
SEK
Annual Cash Flow Reinvestment Rate for Elicera Therapeutics AB (None–None)
Year-by-year capital reinvestment analysis for Elicera Therapeutics AB. For live market cap and broader valuation context, see how much is Elicera Therapeutics AB worth.
| Year | Reinvestment Rate | Total Reinvested (SEK) | Operating CF | Capex | YoY Change |
|---|
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow